Terrell Phillips, DO
Pain Management · Oklahoma City, OKNPI 1871534024
Payments from drug & device makers
Across 448 payments — averaging $68.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20K
- Abbott$3K
- Relievant Medsystems, Inc.$802
- Stratus Medical, LLC$796
- Genesys Orthopedics Systems, L.L.C.$620
- Avanos Medical$602
- plus $5K from 41 others
What the payments were for
- Speaking & faculty fees$16,80055%
- Travel & lodging$2,2367%
- Food & beverage$11,48338%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUCEMYRA$10,230
- RELISTOR$8,168
- Intracept$1,568
- Nimbus$430
- Proclaim DRG IPG$323
- Neuromodulation Dspsbls and Accs$246
- Nalu Neurostimulation System$142
- Proclaim Family of SCS IPGs$141
- mild Device Kit$137
- SPRINT PNS System$132
- Mobi-C$125
- Lucemyra/Lofexidine$125
- SUPERION$120
- Zilretta$107
- COOLIEF* COOLED RADIOFREQUENCY$106
- Morphabond ER$106
- ASCENDA$102
- INTELLIS$101
How this compares
Too few pain management providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 653 | $50,165 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,365 | $43,344 |
| BelbucaBuprenorphine Hcl | 52 | $38,284 |
| Buprenorphine | 115 | $27,666 |
| BelsomraSuvorexant | 39 | $19,360 |
| GraliseGabapentin | 12 | $16,066 |
| LinzessLinaclotide | 25 | $14,099 |
| Xtampza ErOxycodone Myristate | 25 | $13,736 |
| NucyntaTapentadol Hcl | 11 | $12,900 |
| Nucynta ErTapentadol Hcl | 17 | $12,439 |
| SymproicNaldemedine Tosylate | 21 | $9,433 |
| ZtlidoLidocaine | 12 | $8,509 |
| MovantikNaloxegol Oxalate | 20 | $7,853 |
| Hysingla ErHydrocodone Bitartrate | 14 | $6,864 |
| Lidocaine | 69 | $6,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta, Nucynta Er | $584 | $77,359105 claims |
| MerckBelsomra | $27 | $19,36039 claims |
| Almatica Pharma LLCGralise | $15 | $16,06612 claims |
| AbbVieLinzess | $73 | $14,09925 claims |
| Shionogi IncSymproic | $45 | $9,43321 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $111 | $8,50912 claims |
| Redhill Biopharma Inc.Movantik | $81 | $7,85320 claims |
| Eisai Inc.Dayvigo | $96 | $4,88011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other pain management in Oklahoma City
- Jeffery Meyerdel City$153
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.